Biotechnology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Arch Iran Med. 2012 Sep;15(9):549-52.
This study was conducted to determine the effect of fish oil (FO) supplements on high density lipoprotein cholesterol (HDL-C), apolipoprotein-AI (Apo-AI), malondialdehyde (MDA), arylesterase (Aryl), and paraoxonase-1 (PON1) activity in female patients with rheumatoid arthritis (RA).
A total of 90 RA patients were randomly allocated into two groups that were treated with one FO pearl (1 gr) daily or placebo for three months in addition to conventional treatment. HDL-C, Apo-AI, and MDA levels as well as PON1 and Aryl activities were measured before and after treatment. Independent t-test was used to match basal parameters of case and control groups. Paired t-test was used to assess significance of the differences. Correlation was evaluated by Pearsons test and the statistical significance was set at P < 0.05.
No significant differences were noted between FO and placebo patients with regards to age, disease duration, post-menopausal status, conventional therapy, body mass index (BMI), and numbers of swollen and tender joints at the beginning of the study. There were 83 patients who completed the three-month follow up. Serum levels of HDL-C (P = 0.018), Apo-AI (P = 0.165), Aryl (P = 0.026), and PON1 (P = 0.049) activity increased, whereas MDA levels decreased significantly with FO supplementation (P = 0.077). Significant correlations between increased PON1 activity and both HDL-C (P = 0.007, r = 0.419) and Apo-AI (P < 0.001, r = 0.742) concentrations as well as between HDL-C and Apo AI levels (P = 0.01, r = 0.403) were found.
According to the results of this study, FO could increase serum HDL-C and PON1 levels and Aryl activity in female patients with RA.
本研究旨在确定鱼油(FO)补充剂对类风湿关节炎(RA)女性患者高密度脂蛋白胆固醇(HDL-C)、载脂蛋白-AI(Apo-AI)、丙二醛(MDA)、芳基酯酶(Aryl)和对氧磷酶-1(PON1)活性的影响。
将 90 名 RA 患者随机分为两组,分别给予 FO 珍珠(1 克)每日一次或安慰剂,同时接受常规治疗,共治疗三个月。治疗前后测定 HDL-C、Apo-AI 和 MDA 水平以及 PON1 和 Aryl 活性。采用独立 t 检验比较病例组和对照组的基线参数。采用配对 t 检验评估差异的显著性。采用 Pearson 检验评估相关性,以 P < 0.05 为差异有统计学意义。
FO 组和安慰剂组患者在年龄、病程、绝经后状态、常规治疗、体重指数(BMI)和研究开始时肿胀和压痛关节数方面无显著差异。有 83 例患者完成了三个月的随访。FO 补充后血清 HDL-C(P = 0.018)、Apo-AI(P = 0.165)、Aryl(P = 0.026)和 PON1(P = 0.049)活性升高,MDA 水平显著降低(P = 0.077)。PON1 活性升高与 HDL-C(P = 0.007,r = 0.419)和 Apo-AI(P < 0.001,r = 0.742)浓度呈显著正相关,与 HDL-C 和 Apo-AI 水平呈显著正相关(P = 0.01,r = 0.403)。
根据本研究结果,FO 可增加 RA 女性患者血清 HDL-C 和 PON1 水平及 Aryl 活性。